Page last updated: 2024-09-04

febuxostat and Innate Inflammatory Response

febuxostat has been researched along with Innate Inflammatory Response in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (50.00)24.3611
2020's6 (50.00)2.80

Authors

AuthorsStudies
Farzipour, S; Ghasemi, A; Hosseinimehr, SJ; Raeispour, M; Talebpour Amiri, F1
Chiba, K; Iino, T; Kataoka, T; Odake, K; Sudo, A; Tsujii, M1
Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N1
Du, YW; Li, XN; Liu, HB; Wang, TT; Wang, W1
Bittleman, D; Coras, R; Dadpey, B; Guma, M; Hamilton, B; Lauro, K; Liu-Bryan, R; Mikuls, TR; Quehenberger, O; Reilly, SM; Terkeltaub, R; Thorisdottir, H1
Busso, N; Kobayashi, T; Nomura, J; So, A1
Bang, D; Curovic, F; Igel, TF; Katz, SD; Krasnokutsky, S; Lazaro, D; Oh, C; Pike, VC; Pillinger, MH; Romero, AG; Shah, B; Toprover, M1
Ahmed, AAE; Ahmed, MAE; El Morsy, EM1
Busso, N; Ives, A; Nomura, J; So, A; Tamura, M; Tsujimoto, S; Yamanaka, Y1
Busso, N; Ives, A; Kobayashi, T; Matsui, C; Nomura, J; Shirakura, T; So, A; Tamura, M; Tsujimoto, S; Yamanaka, Y1
Agrawal, A; Saigal, R1
Alonso-Pacho, A; de la Puerta González-Quevedo, C; Fabregate-Fuente, M; Sabán-Ruiz, J1

Reviews

2 review(s) available for febuxostat and Innate Inflammatory Response

ArticleYear
Pathogenesis and Clinical Management of Gouty Arthritis.
    The Journal of the Association of Physicians of India, 2015, Volume: 63, Issue:12

    Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Gouty; Colchicine; Diet, Healthy; Febuxostat; Fluid Therapy; Gout Suppressants; Humans; Hyperuricemia; Inflammation; Interleukin 1 Receptor Antagonist Protein; Polyethylene Glycols; Smoking Cessation; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase

2015
Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation.
    Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2013, Volume: 12, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Febuxostat; Heart Failure; Humans; Inflammation; Ischemia; Rabbits; Rats; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Xanthine Oxidase

2013

Trials

1 trial(s) available for febuxostat and Innate Inflammatory Response

ArticleYear
C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study.
    Cardiovascular drugs and therapy, 2023, Volume: 37, Issue:5

    Topics: Atherosclerosis; C-Reactive Protein; Febuxostat; Female; Humans; Hyperuricemia; Inflammation; Male; Treatment Outcome; Uric Acid

2023

Other Studies

9 other study(ies) available for febuxostat and Innate Inflammatory Response

ArticleYear
Febuxostat, an inhibitor of xanthine oxidase, ameliorates ionizing radiation-induced lung injury by suppressing caspase-3, oxidative stress and NF-κB.
    Drug and chemical toxicology, 2022, Volume: 45, Issue:6

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Caspase 3; Febuxostat; Inflammation; Lung Injury; Mice; NF-kappa B; Oxidative Stress; Radiation, Ionizing; Xanthine Oxidase

2022
Febuxostat treatment attenuates oxidative stress and inflammation due to ischemia-reperfusion injury through the necrotic pathway in skin flap of animal model.
    Free radical biology & medicine, 2021, Volume: 177

    Topics: Animals; Disease Models, Animal; Febuxostat; Inflammation; Necrosis; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury

2021
Inhibition of Xanthine Oxidase Protects against Sepsis-Induced Acute Kidney Injury by Ameliorating Renal Hypoxia.
    Oxidative medicine and cellular longevity, 2022, Volume: 2022

    Topics: Acute Kidney Injury; Animals; Febuxostat; Hypoxia; Inflammation; Ischemia; Kidney; Lipopolysaccharides; Mice; Oxygen; Reactive Oxygen Species; RNA, Small Interfering; Sepsis; Xanthine Oxidase

2022
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.
    Arthritis research & therapy, 2022, 07-25, Volume: 24, Issue:1

    Topics: Adipocytes; Allopurinol; Colchicine; Enzyme Inhibitors; Fatty Acids, Nonesterified; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Inflammation; Lipolysis; Prospective Studies; Uric Acid; Xanthine Oxidase

2022
Febuxostat, a Xanthine Oxidoreductase Inhibitor, Decreases NLRP3-dependent Inflammation in Macrophages by Activating the Purine Salvage Pathway and Restoring Cellular Bioenergetics.
    Scientific reports, 2019, 11-21, Volume: 9, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Energy Metabolism; Febuxostat; Humans; Inflammasomes; Inflammation; Macrophages; Mice; Mitochondria; NLR Family, Pyrin Domain-Containing 3 Protein; Primary Cell Culture; Purines; Reactive Oxygen Species; Xanthine Dehydrogenase

2019
Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study.
    Arthritis research & therapy, 2020, 07-11, Volume: 22, Issue:1

    Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Inflammation

2020
Protective effects of febuxostat against paraquat-induced lung toxicity in rats: Impact on RAGE/PI3K/Akt pathway and downstream inflammatory cascades.
    Life sciences, 2019, Mar-15, Volume: 221

    Topics: Acute Lung Injury; Animals; beta Catenin; Febuxostat; Inflammation; Lung; Lung Injury; Male; Oxidative Stress; Paraquat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pulmonary Edema; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Xanthine Oxidase

2019
Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Animals; Cell Line, Tumor; Chemokine CCL2; Dual Specificity Phosphatase 1; Febuxostat; Female; Humans; Inflammation; Lipopolysaccharides; Macrophages; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; Phosphorylation; Reactive Oxygen Species; RNA, Messenger; Thiazoles; Xanthine Oxidase

2013
Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice.
    Scientific reports, 2014, Apr-01, Volume: 4

    Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Cholesterol; Cytokines; Disease Models, Animal; Endothelial Cells; Febuxostat; Gout Suppressants; Inflammation; L-Lactate Dehydrogenase; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Plaque, Atherosclerotic; Reactive Oxygen Species; Thiazoles; Xanthine Oxidase

2014